查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2037568

再生醫學市場預測至2034年—按產品類型、治療方法、應用、最終用戶和地區分類的全球分析

Regenerative Medicine Market Forecasts to 2034 - Global Analysis By Product Type, Therapy Type, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球再生醫學市場規模將達到 629 億美元，並在預測期內以 18.3% 的複合年成長率成長，到 2034 年將達到 2,415 億美元。

再生醫學涵蓋了修復、替換或再生受損人體細胞、組織和器官以恢復其正常功能的先進治療方法。這個創新領域整合了細胞療法、基因編輯、組織工程和生物材料，旨在攻克以往被認為無法治癒的疾病。再生醫學市場正在革新醫療保健，它提供的不再只是症狀管理，而是潛在的治療方法。其應用範圍涵蓋腫瘤學、整形外科、心血管疾病和神經病學等領域。隨著臨床成功案例的累積和法律規範的日益完善，再生醫學正從實驗性介入走向全球主流治療方案。

慢性病和退化性疾病盛行率增加

隨著糖尿病、心血管疾病和神經系統疾病等疾病在全球範圍內的日益增多，人們對再生醫學作為傳統治療方法的替代方案的需求也隨之激增。傳統的藥物治療方法通常只能緩解症狀，而無法解決潛在的組織損傷或器官功能障礙。再生醫學則有望透過刺激人體自身的修復機制來阻止甚至逆轉疾病的進展。已開發國家的老齡化人口尤其容易患上退化性疾病，這導致需要長期治療方案的患者群體不斷擴大。面對慢性疾病帶來的不永續的負擔，醫療保健系統正日益支持再生醫學療法，因為這些療法有望透過根治病因而非持續管理，降低患者的終身治療成本並提高其生活品質。

高昂的研發和製造成本

在全球市場，再生醫學產品的可及性和廣泛應用仍然受到巨大的經濟障礙的限制。細胞療法需要在嚴格的藥品生產品質管理規範 (GMP) 條件下進行複雜的生產流程，包括專用無塵室設施、冷凍保存能力和嚴格的品質檢測方案。這些要求直接導致每劑藥物的生產成本高昂，自體療法的成本往往高達數十萬美元。許多地區的健保報銷機制無法完全涵蓋這種成本結構，為研發者和醫療服務提供者都帶來了不確定性。中小型生物技術公司在獲得足夠的資金以推進有前景的治療方法完成成本高昂的臨床開發項目方面面臨著尤為嚴峻的挑戰。

基因編輯和誘導性多功能幹細胞（iPS細胞）的進展

CRISPR-Cas9 和 iPS 細胞重編程等創新技術正大幅拓展再生醫學的治療可能性。基因編輯技術使得在細胞移植前精準糾正致病突變成為可能，從而有望從根源根除遺傳疾病。源自成人組織的誘導性多功能細胞 (iPSC) 能夠實現患者特異性治療，同時避免了與胚胎幹細胞相關的倫理問題。這些技術正日益融合，用於開發具有更低免疫抗原性風險的現成同種異體移植產品。生產流程也不斷改進，自動化生物反應器系統和閉迴路製程技術降低了生產成本，並實現了大規模的生產。這些進步正在吸引大量投資，並加速多個治療領域的臨床研發。

監管方面的不確定性和安全性問題

不斷變化的法規結構和尚未解決的安全問題為市場擴張和產品核可進度帶來了重大挑戰。再生醫學產品的獨特生物學特性意味著傳統的藥物評估模式可能無法充分反映致瘤性和不良免疫反應等長期風險，因此需要採取相應的評估方法。全球監管機構正在實施不同的框架，這增加了尋求全球商業化策略的企業的複雜性。一些引人注目的臨床挫折和安全問題導致對新候選藥物的審查力度加大，審查週期延長。雖然這種謹慎的監管方式能夠保護病患安全，但也可能造成商業性的不確定性，阻礙投資，並延遲病患獲得突破性治療方法的機會。

新冠疫情的影響：

新冠疫情對再生醫學市場產生了複雜且矛盾的影響。由於醫療資源被調往抗疫，臨床試驗受到嚴重干擾，非緊急適應症的患者招募也大幅放緩。供應鏈中斷影響了細胞生產所需的特殊原料和耗材的供應。然而，疫情也加速了先進治療方法生產技術的應用，包括分散式生產模式和數位化品管系統。監管機構對某些再生醫學產品實施了快速核准流程，展現出一定的柔軟性甚至可能在疫情結束後繼續維持。再生醫學領域的創業投資也展現出韌性，即使在疫情最嚴重的時期，仍有幾輪引人注目的資金籌措進行。

在預測期內，自體療法領域預計將佔據最大的市場佔有率。

自體療法預計將在預測期內佔據最大的市場佔有率，這反映了其成熟的臨床基礎和良好的安全性。由於這些治療方法利用的是取自患者自身身體的細胞，因此消除了免疫排斥的風險以及移植後使用免疫抑制劑的需求。自體療法的成熟應用，例如軟骨修復、骨移植和皮膚修復，已累積了大量的臨床證據，支持其療效和安全性。與異體療法相比，自體產品的監管核准流程通常更為簡便，因為免疫相容性問題從根本上就不存在。儘管這些治療方法由於其個體化特性而存在規模化方面的局限性，但在個人化治療能夠帶來更佳臨床療效的應用領域，預計它們仍將保持優勢。

在預測期內，神經病學領域預計將呈現最高的複合年成長率。

在預測期內，神經病學領域預計將呈現最高的成長率，這主要得益於神經退化性疾病治療方面巨大的未滿足需求。對於帕金森氏症、阿茲海默症、多發性硬化症和脊髓損傷等疾病，目前缺乏有效的疾病修正治療，而藥物治療也僅能提供有限的症狀治療。幹細胞移植、神經營養因子傳遞和細胞替代療法等再生醫學方法在臨床前和早期臨床試驗中展現前所未有的潛力。神經科學研究在理解神經可塑性和再生機制方面的進展正在加速治療方法的發展。領先的製藥公司正加大對以神經病學為重點的再生醫學計畫的投入，他們認知到全球人口老化帶來的巨大商業性機會。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於生物技術創新叢集的集中、充足的研究經費以及有利的監管環境。美國在全球再生醫學發展中處於領先地位，擁有大多數上市的細胞和基因治療公司以及領先的學術研究中心。包括FDA的「先進再生療法」（RMAT）認定在內的快速核准程序，在確保安全標準的同時，加快了產品核准。強而有力的智慧財產權保護和大量的創業投資投資，為創新治療方法從概念到商業化的推進創造了有利環境。針對某些細胞療法（尤其是在腫瘤領域）建立的完善的報銷機制，證明了商業性可行性，並鼓勵對其他治療領域的持續投資。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於政府的戰略舉措、具有競爭力的製造成本以及快速現代化的醫療基礎設施。日本、韓國、中國和新加坡等國家已實施專門的法規結構，旨在加速再生醫學的發展，同時確保病人安全。日本的細胞療法有條件核准制度使得患者能夠儘早獲得治療，並產生支持更廣泛應用的真實世界數據。該地區的合約研發生產機構（CDMO）提供具成本效益的生產能力，吸引了國際夥伴關係。隨著區域生產能力的擴大和監管的協調統一，亞太地區正在崛起為臨床研發中心和重要的商業市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球再生醫學市場：依產品類型分類

  • 細胞療法
    • 幹細胞療法
    • 非幹細胞療法
  • 基因治療
  • 組織工程
  • 生物製藥和小分子化合物

第6章：全球再生醫學市場：依治療方法

  • 自體療法
  • 順勢療法

第7章 全球再生醫學市場：依應用領域分類

  • 腫瘤學
  • 整形外科和肌肉骨骼疾病
  • 心血管疾病
  • 神經病學
  • 皮膚科和創傷治療
  • 糖尿病
  • 眼科
  • 其他用途

第8章 全球再生醫學市場：依最終用戶分類

  • 醫院和診所
  • 門診手術中心
  • 研究和學術機構
  • 生物製藥和生物技術公司

第9章 全球再生醫學市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Astellas Pharma Inc
  • Novartis AG
  • Fujifilm Holdings Corporation
  • Vericel Corporation
  • Mesoblast Limited
  • Stryker Corporation
  • Integra LifeSciences Holdings Corporation
  • Smith & Nephew plc
  • Organogenesis Holdings Inc
  • CRISPR Therapeutics AG
  • Editas Medicine Inc
  • Bluebird Bio Inc
  • Vertex Pharmaceuticals Incorporated
  • Takeda Pharmaceutical Company Limited
  • Bristol Myers Squibb Company
Product Code: SMRC35983

According to Stratistics MRC, the Global Regenerative Medicine Market is accounted for $62.9 billion in 2026 and is expected to reach $241.5 billion by 2034 growing at a CAGR of 18.3% during the forecast period. Regenerative medicine encompasses advanced therapeutic approaches that repair, replace, or regenerate damaged human cells, tissues, and organs to restore normal function. This transformative field integrates cell therapies, gene editing, tissue engineering, and biomaterials to address conditions previously considered untreatable. The market is revolutionizing healthcare by offering potential cures rather than symptom management, with applications spanning oncology, orthopedics, cardiovascular diseases, and neurology. As clinical successes accumulate and regulatory pathways mature, regenerative medicine is transitioning from experimental interventions to mainstream therapeutic options worldwide.

Market Dynamics:

Driver:

Increasing prevalence of chronic and degenerative diseases

Rising global incidence of conditions such as diabetes, cardiovascular disorders, and neurological diseases is creating urgent demand for regenerative treatment alternatives. Traditional pharmaceutical approaches often manage symptoms without addressing underlying tissue damage or organ dysfunction. Regenerative medicine offers the potential to halt or reverse disease progression by stimulating the body's natural healing mechanisms. Aging populations across developed nations are particularly susceptible to degenerative conditions, expanding the patient pool requiring long-term therapeutic solutions. Healthcare systems facing unsustainable chronic disease burdens are increasingly supporting regenerative approaches that may reduce lifetime treatment costs and improve patient quality of life through definitive interventions rather than ongoing management.

Restraint:

High development and manufacturing costs

Significant financial barriers continue to limit the accessibility and scalability of regenerative medicine products across global markets. Cell-based therapies require complex manufacturing processes under stringent good manufacturing practice conditions, including specialized cleanroom facilities, cryopreservation capabilities, and rigorous quality testing protocols. These requirements translate into high per-dose production costs, often reaching hundreds of thousands of dollars for individualized autologous treatments. Reimbursement frameworks in many regions have not fully adapted to these cost structures, creating uncertainty for both developers and healthcare providers. Small and mid-sized biotechnology companies face particular challenges securing sufficient capital to advance promising candidates through expensive clinical development programs.

Opportunity:

Advancements in gene editing and induced pluripotent stem cells

Revolutionary technologies such as CRISPR-Cas9 and iPSC reprogramming are dramatically expanding the therapeutic possibilities within regenerative medicine. Gene editing enables precise correction of disease-causing mutations before cell transplantation, potentially eliminating genetic disorders at their source. Induced pluripotent stem cells derived from adult tissues circumvent ethical concerns associated with embryonic stem cells while enabling patient-specific therapies. These technologies are increasingly being combined to create off-the-shelf allogeneic products with reduced immunogenicity risks. Manufacturing processes are steadily improving, with automated bioreactor systems and closed processing technologies reducing production costs and enabling greater scale. These advancements attract substantial investment and accelerate the clinical pipeline across multiple therapeutic areas.

Threat:

Regulatory uncertainty and safety concerns

Evolving regulatory frameworks and unresolved safety questions pose significant challenges to market expansion and product approval timelines. The unique biological nature of regenerative products requires adapted evaluation approaches, as traditional pharmaceutical assessment paradigms may not adequately capture long-term risks such as tumorigenicity or unwanted immune responses. Regulatory agencies worldwide have implemented varying frameworks, creating complexity for companies pursuing global commercialization strategies. High-profile clinical setbacks and safety incidents have increased scrutiny and extended review periods for novel candidates. This regulatory caution, while protecting patient safety, creates commercial uncertainty that may deter investment and delay patient access to potentially transformative therapies.

Covid-19 Impact:

The COVID-19 pandemic generated complex and contradictory effects on the regenerative medicine market landscape. Clinical trials faced significant disruptions as healthcare resources were redirected toward pandemic response and patient enrollment slowed dramatically across non-urgent indications. Supply chain interruptions affected the availability of specialized raw materials and consumables essential for cell manufacturing. However, the pandemic also accelerated adoption of advanced therapy manufacturing technologies, including decentralized production models and digital quality management systems. Regulatory agencies implemented expedited review pathways for certain regenerative products, demonstrating flexibility that may persist post-pandemic. Venture capital investment in regenerative medicine demonstrated resilience, with several notable financings occurring during the most disruptive pandemic periods.

The Autologous Therapies segment is expected to be the largest during the forecast period

The Autologous Therapies segment is expected to account for the largest market share during the forecast period, reflecting the established clinical foundation and favorable safety profile of patient-derived treatments. These therapies utilize cells harvested from the patient's own body, eliminating immune rejection risks and the need for immunosuppressive medications following transplantation. Well-established autologous applications including cartilage repair, bone grafting, and skin regeneration have generated extensive clinical evidence supporting their efficacy and safety. Regulatory approval pathways for autologous products are generally more straightforward compared to allogeneic alternatives, as immune compatibility concerns are inherently addressed. The personalized nature of these treatments, while limiting scalability, ensures continued dominance in applications where individualized therapy yields superior clinical outcomes.

The Neurology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Neurology segment is predicted to witness the highest growth rate, driven by the enormous unmet medical need for neurodegenerative disease treatments. Conditions including Parkinson's disease, Alzheimer's disease, multiple sclerosis, and spinal cord injuries have historically lacked effective disease-modifying therapies, with pharmacological approaches offering only modest symptomatic relief. Regenerative medicine approaches including stem cell transplantation, neurotrophic factor delivery, and cell replacement strategies are showing unprecedented promise in preclinical and early clinical studies. Neuroscience research advancements in understanding neural plasticity and regeneration mechanisms are accelerating therapeutic development. Major pharmaceutical companies are increasingly investing in neurology-focused regenerative programs, recognizing the substantial commercial opportunity presented by aging populations worldwide.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by concentrated biotechnology innovation clusters, substantial research funding, and favorable regulatory pathways. The United States leads global regenerative medicine development, housing the majority of publicly traded cell and gene therapy companies and academic centers of excellence. The FDA's expedited programs including Regenerative Medicine Advanced Therapy (RMAT) designation have accelerated product approvals while maintaining safety standards. Strong intellectual property protection and substantial venture capital investment create an environment where innovative therapies can advance from concept to commercialization. Established reimbursement frameworks for certain cell therapies, particularly in oncology, provide commercial validation that encourages continued investment across additional therapeutic areas.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by government strategic initiatives, competitive manufacturing costs, and rapidly modernizing healthcare infrastructure. Countries including Japan, South Korea, China, and Singapore have implemented regulatory frameworks specifically designed to accelerate regenerative medicine development while ensuring patient safety. Japan's conditional approval pathway for cell therapies has enabled earlier patient access and generated real-world evidence supporting broader adoption. Contract development and manufacturing organizations across the region offer cost-effective production capabilities attracting international partnerships. As regional manufacturing capacity expands and regulatory harmonization progresses, Asia Pacific emerges as both a clinical development hub and significant commercial market.

Key players in the market

Some of the key players in Regenerative Medicine Market include Astellas Pharma Inc, Novartis AG, Fujifilm Holdings Corporation, Vericel Corporation, Mesoblast Limited, Stryker Corporation, Integra LifeSciences Holdings Corporation, Smith & Nephew plc, Organogenesis Holdings Inc, CRISPR Therapeutics AG, Editas Medicine Inc, Bluebird Bio Inc, Vertex Pharmaceuticals Incorporated, Takeda Pharmaceutical Company Limited, and Bristol Myers Squibb Company.

Key Developments:

In April 2026, Mesoblast announced it is preparing for a potential U.S. FDA resubmission for remestemcel-L (for pediatric GVHD) following successful completion of additional potency assay validations requested by the agency.

In October 2025, Novartis presented Phase III STEER study data, demonstrating statistically significant motor function improvement in older SMA patients, paving the way for the recent EU regulatory success.

In May 2025, Astellas completed the expansion of its in-house manufacturing capabilities for diverse modalities, including iPSC-derived cell therapies, to reduce reliance on external CDMOs for clinical trials.

Product Types Covered:

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Biologics & Small Molecules

Therapy Types Covered:

  • Autologous Therapies
  • Allogeneic Therapies

Applications Covered:

  • Oncology
  • Orthopedics & Musculoskeletal Disorders
  • Cardiovascular Diseases
  • Neurology
  • Dermatology & Wound Healing
  • Diabetes
  • Ophthalmology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Research & Academic Institutes
  • Biopharmaceutical & Biotechnology Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Regenerative Medicine Market, By Product Type

  • 5.1 Cell Therapy
    • 5.1.1 Stem Cell Therapy
    • 5.1.2 Non-Stem Cell Therapy
  • 5.2 Gene Therapy
  • 5.3 Tissue Engineering
  • 5.4 Biologics & Small Molecules

6 Global Regenerative Medicine Market, By Therapy Type

  • 6.1 Autologous Therapies
  • 6.2 Allogeneic Therapies

7 Global Regenerative Medicine Market, By Application

  • 7.1 Oncology
  • 7.2 Orthopedics & Musculoskeletal Disorders
  • 7.3 Cardiovascular Diseases
  • 7.4 Neurology
  • 7.5 Dermatology & Wound Healing
  • 7.6 Diabetes
  • 7.7 Ophthalmology
  • 7.8 Other Applications

8 Global Regenerative Medicine Market, By End User

  • 8.1 Hospitals & Clinics
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Biopharmaceutical & Biotechnology Companies

9 Global Regenerative Medicine Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Astellas Pharma Inc
  • 12.2 Novartis AG
  • 12.3 Fujifilm Holdings Corporation
  • 12.4 Vericel Corporation
  • 12.5 Mesoblast Limited
  • 12.6 Stryker Corporation
  • 12.7 Integra LifeSciences Holdings Corporation
  • 12.8 Smith & Nephew plc
  • 12.9 Organogenesis Holdings Inc
  • 12.10 CRISPR Therapeutics AG
  • 12.11 Editas Medicine Inc
  • 12.12 Bluebird Bio Inc
  • 12.13 Vertex Pharmaceuticals Incorporated
  • 12.14 Takeda Pharmaceutical Company Limited
  • 12.15 Bristol Myers Squibb Company

List of Tables

  • Table 1 Global Regenerative Medicine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Regenerative Medicine Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Regenerative Medicine Market Outlook, By Cell Therapy (2023-2034) ($MN)
  • Table 4 Global Regenerative Medicine Market Outlook, By Stem Cell Therapy (2023-2034) ($MN)
  • Table 5 Global Regenerative Medicine Market Outlook, By Non-Stem Cell Therapy (2023-2034) ($MN)
  • Table 6 Global Regenerative Medicine Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 7 Global Regenerative Medicine Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 8 Global Regenerative Medicine Market Outlook, By Biologics & Small Molecules (2023-2034) ($MN)
  • Table 9 Global Regenerative Medicine Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 10 Global Regenerative Medicine Market Outlook, By Autologous Therapies (2023-2034) ($MN)
  • Table 11 Global Regenerative Medicine Market Outlook, By Allogeneic Therapies (2023-2034) ($MN)
  • Table 12 Global Regenerative Medicine Market Outlook, By Application (2023-2034) ($MN)
  • Table 13 Global Regenerative Medicine Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 14 Global Regenerative Medicine Market Outlook, By Orthopedics & Musculoskeletal Disorders (2023-2034) ($MN)
  • Table 15 Global Regenerative Medicine Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 16 Global Regenerative Medicine Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 17 Global Regenerative Medicine Market Outlook, By Dermatology & Wound Healing (2023-2034) ($MN)
  • Table 18 Global Regenerative Medicine Market Outlook, By Diabetes (2023-2034) ($MN)
  • Table 19 Global Regenerative Medicine Market Outlook, By Ophthalmology (2023-2034) ($MN)
  • Table 20 Global Regenerative Medicine Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 21 Global Regenerative Medicine Market Outlook, By End User (2023-2034) ($MN)
  • Table 22 Global Regenerative Medicine Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 23 Global Regenerative Medicine Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 24 Global Regenerative Medicine Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 25 Global Regenerative Medicine Market Outlook, By Biopharmaceutical & Biotechnology Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.